A

AgilentB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$178.00

Analysis reference price unavailable

Analysis 2026-09-16 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$160.00

Analysis reference price unavailable

Analysis 2026-09-16 · RankAlpha Sentiment Codex

B-

Bear case

20%

Probability

Target price

$128.00

Analysis reference price unavailable

Analysis 2026-09-16 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-16

AI commentary

Primary-source tone is constructive following the Q3 beat and raised FY2026 outlook. However, no reliable social, options, short-interest, employee-sentiment, immediate post-release price-reaction, or verified analyst-revision data were supplied; unavailable sentiment fields are left neutral rather than treated as positive evidence. The setup remains favorable but requires Q4 confirmation without another tariff refund [#SEC-8K-2026-08-26].

RankAlpha Sentiment Codex - 2026-09-16

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-31eventQ4 execution against raised FY2026 outlookMedium impact

Agilent guided Q4 revenue to $1.98-$2.00 billion, core growth to 5.2%-6.2%, and non-GAAP EPS to $1.71-$1.74 after Q3 revenue and EPS exceeded prior guidance. Delivery would reinforce the operating-momentum thesis [#SEC-8K-2026-08-26].

2026-10-31catalystUnderlying earnings must offset the nonrecurring tariff benefitMedium impact

Q3 non-GAAP EPS included a $0.06 tariff-refund benefit, while Q4 guidance assumes no future tariff refunds. Failure to sustain margins without that benefit could weaken the positive earnings interpretation [#SEC-8K-2026-08-26][#PR-EARNINGS-2026-08-31].

2026-10-31catalystBiocare acquisition and pathology expansionMedium impact

The previously announced Biocare Medical acquisition was targeted to close by fiscal Q4 2026. Timely completion and integration could expand Agilent's pathology exposure, but the packet does not confirm completion as of the analysis date [#PR-2026-03-09].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-16 • Updated nightlySource: Internal modelMethodology